8-K Announcements
6Material company update
May 18, 2026·SEC
Material company update
May 14, 2026·SEC
Material company update
May 8, 2026·SEC
Cellectar Biosciences, Inc.(CLRB)Earnings, Financials & Key Ratios
CLRB•NASDAQ
$2.83
Price updated Jul 2, 2026
AboutCellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.Show more
- Revenue$0
- EBITDA-$23M+55.8%
- Net Income-$22M+51.1%
- EPS (Diluted)-8.35+80.1%
- ROE-179.99%+99.0%
CLRB Price & Volume
Cellectar Biosciences, Inc. (CLRB) stock price & volume — 10-year historical chart
Loading chart...
Persistent Clinical Burn Challenges Capital Structure Viability
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Capital structure dilution risk
Key Thesis Takeaways
- Cellectar Biosciences remains a high-risk, pre-revenue biotechnology firm whose long-term viability is tethered to the successful clinical advancement of its proprietary PDC platform.
- While the company continues to prioritize R&D, the lack of commercial revenue and a rapidly depleting cash position suggest significant ongoing reliance on dilutive financing.
- Investors should monitor the company's ability to manage its $1.5 million debt load against a backdrop of accumulated deficits that reached $274.8 million as of 2026Q1.
Verdict Logic
the company's precarious liquidity position, evidenced by a cash balance of only $8.3 million against persistent quarterly operating losses of $5.8 million, suggests a high probability of further dilutive capital raises.
CLRB Growth Metrics
Cellectar Biosciences, Inc. (CLRB) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM15.09%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM67.34%
Return on Capital
10 Years-507.81%
5 Years-1014.1%
3 Years-1934.32%
Last Year-174.65%
Peers Comparison
Key metrics vs top competitors for Cellectar Biosciences, Inc. (CLRB)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.83 | $9.03M | -0.34 | — | — | -179.99% | — | |
| $17.54 | $42.33M | -0.38 | -3.5% | -624.59% | -16.12% | — | |
| $10.18 | $299.1M | -2.03 | -92.81% | -8550.65% | — | — | |
| $201.10 | $29.3B | 21.15 | 9.84% | 27.44% | 24.41% | — | |
| $123.60 | $9.09B | -21.13 | — | — | -42.78% | — | |
| $3.41 | $142M | -1002.94 | 10.37% | 52.16% | — | — |
Compare CLRB vs Peers
Cellectar Biosciences, Inc. (CLRB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CLRB SEC Filings & Documents
Cellectar Biosciences, Inc. (CLRB) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when CLRB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CLRB Frequently Asked Questions
Cellectar Biosciences, Inc. (CLRB) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is CLRB profitable?
Cellectar Biosciences, Inc. (CLRB) reported a net loss of $20.8M for fiscal year 2025.
Dividend & Returns
What is CLRB's return on equity?
Cellectar Biosciences, Inc. (CLRB) has a return on equity (ROE) of -180.0%. Negative ROE indicates the company is unprofitable.
What is Cellectar Biosciences, Inc.'s free cash flow?
Cellectar Biosciences, Inc. (CLRB) had negative free cash flow of $18.6M in fiscal year 2025, likely due to heavy capital investments.